Pharmaceutical Origin Transparency Act of 2018

Bill: 115-s-3105
Sponsor: full_name: Sen. McCaskill, Claire [D-MO]
Introduced: 2018-06-21
Policy area: Health
Latest action: action_date: 2018-06-21
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2018-06-21
action_desc: Introduced in Senate
text: <p><b>Pharmaceutical Origin Transparency Act of 2018 </b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require a drug manufacturer to publish information about each country in which its drugs are manufactured. (A drug is manufactured in a country if the active pharmaceutical ingredient is manufactured in such country.)</p>

tv_txt: II 115th CONGRESS 2d Session S. 3105 IN THE SENATE OF THE UNITED STATES June 21, 2018 Mrs. McCaskill introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require manufacturers of drugs to post the names of the countries in which their drugs are manufactured on their internet websites.

1. Short title This Act may be cited as the Pharmaceutical Origin Transparency Act of 2018 . 2. Information about drug manufacturing Section 301 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 331 ) is amended by adding at the end the following: (eee) (1) The introduction or delivery for introduction into interstate commerce of any drug subject to section 503(b)(1), unless the manufacturer of such drug maintains on its internet website information about each country in which such drug is manufactured. (2) For purposes of this paragraph, a drug is manufactured in a country if the active pharmaceutical ingredient is manufactured in such country. .